BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33823933)

  • 1. Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples.
    Lobo J; Constâncio V; Leite-Silva P; Guimarães R; Cantante M; Braga I; Maurício J; Looijenga LHJ; Henrique R; Jerónimo C
    Clin Epigenetics; 2021 Apr; 13(1):70. PubMed ID: 33823933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
    Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
    Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy.
    Singh R; Fazal Z; Bikorimana E; Boyd RI; Yerby C; Tomlin M; Baldwin H; Shokry D; Corbet AK; Shahid K; Hattab A; Freemantle SJ; Spinella MJ
    Mol Oncol; 2022 Feb; 16(3):683-698. PubMed ID: 34482638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypermethylation and global remodelling of DNA methylation is associated with acquired cisplatin resistance in testicular germ cell tumours.
    Fazal Z; Singh R; Fang F; Bikorimana E; Baldwin H; Corbet A; Tomlin M; Yerby C; Adra N; Albany C; Lee S; Freemantle SJ; Nephew KP; Christensen BC; Spinella MJ
    Epigenetics; 2021 Oct; 16(10):1071-1084. PubMed ID: 33126827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
    Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
    Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.
    Schmidtova S; Kalavska K; Kucerova L
    Curr Oncol Rep; 2018 Sep; 20(11):88. PubMed ID: 30259297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent.
    Piulats JM; Vidal A; García-Rodríguez FJ; Muñoz C; Nadal M; Moutinho C; Martínez-Iniesta M; Mora J; Figueras A; Guinó E; Padullés L; Aytés À; Molleví DG; Puertas S; Martínez-Fernández C; Castillo W; Juliachs M; Moreno V; Muñoz P; Stefanovic M; Pujana MA; Condom E; Esteller M; Germà JR; Capella G; Farré L; Morales A; Viñals F; García-Del-Muro X; Cerón J; Villanueva A
    Clin Cancer Res; 2018 Aug; 24(15):3755-3766. PubMed ID: 29618620
    [No Abstract]   [Full Text] [Related]  

  • 8. Global DNA methylation analysis reveals miR-214-3p contributes to cisplatin resistance in pediatric intracranial nongerminomatous malignant germ cell tumors.
    Hsieh TH; Liu YR; Chang TY; Liang ML; Chen HH; Wang HW; Yen Y; Wong TT
    Neuro Oncol; 2018 Mar; 20(4):519-530. PubMed ID: 29036598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours.
    Rudolph C; Melau C; Nielsen JE; Vile Jensen K; Liu D; Pena-Diaz J; Rajpert-De Meyts E; Rasmussen LJ; Jørgensen A
    Cell Oncol (Dordr); 2017 Aug; 40(4):341-355. PubMed ID: 28536927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
    Nitzsche B; Gloesenkamp C; Schrader M; Hoffmann B; Zengerling F; Balabanov S; Honecker F; Höpfner M
    Br J Cancer; 2012 Nov; 107(11):1853-63. PubMed ID: 23169338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors - clinical Implications.
    Kalavska K; Conteduca V; De Giorgi U; Mego M
    Curr Cancer Drug Targets; 2018; 18(10):967-978. PubMed ID: 29295694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetics: a way to understand the origin and biology of testicular germ cell tumors.
    Okamoto K
    Int J Urol; 2012 Jun; 19(6):504-11. PubMed ID: 22375557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonal analyses of refractory testicular germ cell tumors.
    Barrett MT; Lenkiewicz E; Malasi S; Stanton M; Slack J; Andrews P; Pagliaro L; Bryce AH
    PLoS One; 2019; 14(3):e0213815. PubMed ID: 30870501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
    Feldman DR; Iyer G; Van Alstine L; Patil S; Al-Ahmadie H; Reuter VE; Bosl GJ; Chaganti RS; Solit DB
    Clin Cancer Res; 2014 Jul; 20(14):3712-20. PubMed ID: 24812411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors.
    Beyrouthy MJ; Garner KM; Hever MP; Freemantle SJ; Eastman A; Dmitrovsky E; Spinella MJ
    Cancer Res; 2009 Dec; 69(24):9360-6. PubMed ID: 19951990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
    Selfe J; Goddard NC; McIntyre A; Taylor KR; Renshaw J; Popov SD; Thway K; Summersgill B; Huddart RA; Gilbert DC; Shipley JM
    J Pathol; 2018 Feb; 244(2):242-253. PubMed ID: 29160922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of
    Timmerman DM; Eleveld TF; Gillis AJM; Friedrichs CC; Hillenius S; Remmers TL; Sriram S; Looijenga LHJ
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours.
    Mendoza J; Martínez J; Hernández C; Pérez-Montiel D; Castro C; Fabián-Morales E; Santibáñez M; González-Barrios R; Díaz-Chávez J; Andonegui MA; Reynoso N; Oñate LF; Jiménez MA; Núñez M; Dyer R; Herrera LA
    Br J Cancer; 2013 Jul; 109(1):68-75. PubMed ID: 23807173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential New Therapeutic Approaches for Cisplatin-Resistant Testicular Germ Cell Tumors.
    Lengert AVH; Pereira LDNB; Cabral ERM; Gomes INF; Jesus LM; Gonçalves MFS; Rocha AOD; Tassinari TA; Silva LSD; Laus AC; Vidal DO; Pinto MT; Reis RM; Lopes LF
    Front Biosci (Landmark Ed); 2022 Aug; 27(8):245. PubMed ID: 36042160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
    Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
    PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.